Chapter 86 - Antimycobacterial Agents- Drugs For Tb, Leprosy

  • April 2020
  • PDF

This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA


Overview

Download & View Chapter 86 - Antimycobacterial Agents- Drugs For Tb, Leprosy as PDF for free.

More details

  • Words: 1,681
  • Pages: 6
CHAPTER 86 ANTIMYCOBACTERIAL AGENTS: DRUGS FOR TUBERCULOSIS, LEPROSY, AND MYCOBACTERIUM AVIUM COMPLEX INFECTION Infections caused by three mycobacteria which are slow growing microbes, and the infections they cause require prolonged treatment - because treatment is prolonged, drug toxicity and poor patient compliance are significant clinical problems - prolonged treatment promotes the emergence of drug-resistant microbes

I.

TUBERCULOSIS I: CLINICAL CONSIDERATIONS

- a global epidemic - transmitted from person to person by inhaling infected sputum that has been aerosolized, usually by coughing or sneezing - initial infection is in the lung - taken up by phagocytic cells - can spread from the lungs to other organs via the lymphatic and circulatory systems - in the absence of treatment, there is always some risk that latent infection may become active A.

DIAGNOSIS AND TREATMENT OF ACTIVE TUBERCULOSIS - goal of treatment is to eliminate symptoms and prevent relapse - treatment must kill tubercle bacilli that are actively dividing as well as those that are “resting” - success is indicated by an absence of observable mycobacteria in sputum and by the failure of sputum cultures to yield colonies - diagnosis testing is indicated for: • individuals with clinical manifestations that suggest tuberculosis • individuals with a positive tuberculin skin test - definitive diagnosis is made with a chest radiograph and microbiologic evaluation of sputum - sputum evaluations: microscopic examination of sputum smears culturing sputum samples - microscopic exam cannot provide a definitive diagnosis because direct observation cannot distinguish between M. Tuberculosis and other mycobacteria - less sensitive than culturing - sputum cultures are often delayed by as long as 3 – 6 weeks - with newer culturing techniques, results can be obtained in less than 1 week - cultures are necessary to determine drug sensitivity 1. Drugs

Prime Directive: Always Treat Tuberculosis with Two or More

- antituberculosis regimens must always contain two or more drugs to which the infecting

organism is sensitive - resistance occurs because of spontaneous mutations - each mutational event confers resistance to only one drug - mutations conferring resistance to a single drug occur in about 1 in every 100 million bacteria - bacterial burden in active tuberculosis is well above 100 million organisms but far below 1016 - tuberculosis grows slowly, hence treatment is prolonged - not only do drug combinations decrease the risk of resistance, combination therapy can reduce the incidence of relapse - because treatment is prolonged, there is a high risk that drug-resistant bacilli will emerge if only one antituberculosis agent is employed - minimizes the risk of drug resistance 2. Drug-Sensitive Tubercle Bacilli and Duration of Treatment - induction phase lasts 2 months, consists of daily therapy with four drugs: • isoniazid • rifampin • pyrazinamide • ethambutol - continuation phase lasts 4 months, consists of daily therapy or biweekly therapy with just two drugs: • isoniazid • rifampin - treatment requires at least three drugs to which the organism is sensitive and should continue for 12 – 24 months after sputum conversion - ideal duration of treatment has not been established - minimal duration is 6 months - hopefully, with treatment, the patient will have an improved recovery in about 3 months B.

DIAGNOSIS AND TREATMENT OF LATENT TUBERCULOSIS 1. How Do We Test for Latent Tuberculosis? - tuberculosis skin test is the primary tool used to identify individuals with latent tuberculosis - performed by giving an intradermal injection of preparation known as purified protein derivative (PPD), an antigen derived from M. Tuberculosis - if individual has an intact immune system and has been exposed to M. Tuberculosis in the past, the PPD will elicit a local immune response - the test is read 48 – 72 hours after the injection - positive reaction is indicated by a region of induration (hardness) around the

injection site 2.

Who Should be Tested? - those having acquired the infection recently - progression from latent tuberculosis to active tuberculosis - these include people with HIV infection, people receiving immunosuppressive drugs, recent contacts of tuberculosis patients, and people with high-risk medical conditions, such as diabetes mellitus, silicosis, or chronic renal failure 3.

Interpreting the Results: Who Should be Treated? - those at high risk, treatment is recommended if the region of induration is relatively small (5 mm or larger) - those at moderate risk, treatment is indicated when the region of induration is larger (10 mm or more) - those at low risk (who should not be routinely tested), the region must be larger still (15 mm or more) to justify treatment 4. Isoniazid – preferred treatment for latent tuberculosis in all patients, including those who are HIV positive - hepatotoxic - to reduce the risk of liver injury, liver function should be evaluated at the beginning of therapy and every 4 weeks thereafter 5. Rifampin – two months of daily therapy with rifampin plus pyrazinamide is as effective as 9 months daily isoniazid - more expensive the isoniazid - greater risk of liver injury than isoniazid

II.

TUBERCULOSIS II: PHARMACOLOGY

OF

INDIVIDUAL ANTITUBERCULOSIS DRUGS

- first-line drugs are isoniazid, rifampin, rifapentine, rifabutin, pyrazinamide, ethambutol - isoniazid and rifampin are the most important - second-line drugs are para-aminosalicylic acid, kanamycin, amikacin, capremycin, ethionamide, cycloserine, ciprofloxacin, and ofloxacin - generally less effective and more toxic than the primary drugs A.

ISONIAZID - primary agent for treatment and prophylaxis of tuberculosis - administered orally (tablets and syrup) and IM - parenteral therapy is administered in critical situations when oral treatment is not possible - widely distributed to tissues and body fluids - inactivated in the liver, primarily by acetylation

- excreted in the urine 1. Therapeutic Uses – indicated only for treating active and latent tuberculosis - when used for active tuberculosis, must be given in combination with at least one other antituberculosis agent (rifampin) 2.

Adverse Effects - peripheral neuropathy = most common adverse effect - symptoms are symmetric paresthesias (tingling, numbness, burning, pain) of the hands and feet - clumsiness, unsteadiness, and muscle aches may also develop - hepatotoxicity = can cause hepatocellular injury and multilobular necrosis - deaths have occurred - greatest risk factor for liver damage is advancing age - should inform patients about signs of hepatitis (anorexia, malaise, fatigue, nausea, yellowing of the skin or eyes) - patients should undergo monthly evaluation for these signs - variety of central nervous system (CNS) effects can occur - include optic neuritis, seizures, dizziness, ataxia, and psychologic disturbances (depression, agitation, impairment of memory, hallucinations, toxic psychosis) - anemia - GI distress, dry mouth and urinary retention - allergy with fever, rashes, and a syndrome resembling lupus erythematosus 3.

Drug Interactions a. Phenytoin - can interfere with the metabolism causing the anticonvulsant to accumulate to toxic levels - signs of excess include ataxia and incoordination b.

Alcohol, Rifampin, and Pyrazinamide – increases the risk of

hepatotoxicity B.

RIFAMPIN (RIFADIN, RIMACTANE) - broad spectrum antibiotic - well absorbed if taken on an empty stomach - both the rate and extent of absorption can be significantly reduced - widely distributed to tissues and body fluids, including CSF - eliminated primarily by hepatic metabolism 1.

Therapeutic Use – one of the most effective antituberculosis drugs

- drug of choice for treating pulmonary tuberculosis and disseminated disease - always employed in combination with at least one other antituberculosis agent - has become an important agent for the treatment of leprosy 2.

Adverse Effects – generally well tolerated - rarely causes significant toxicity - hepatotoxicity = toxic to the liver and may cause jaundice and even hepatitis - patients should be monitored closely for signs of liver dysfunction - tests of liver function (serum transaminase levels) should be made prior to treatment and every 2 – 4 weeks thereafter - patients should be informed about signs of hepatitis (jaundice, anorexia, malaise, fatigue, nausea) - frequently imparts a red-orange color to urine, sweat, saliva, and tears - patients should be forewarned of this harmless effect - permanent staining of soft contact lenses has occurred - gastrointestinal disturbances (anorexia, nausea, abdominal discomfort) - cutaneous reactions (flushing, itching, rash) - rarely, flu-like syndrome characterized by fever, chills, muscle aches, headache, and dizziness - appears to have an immunologic basis - shortness of breath, hemolytic anemia, shock, and acute renal failure 3. Drug Interactions – can hasten the metabolism of many drugs, reducing their effects - special concern with oral contraceptives (women should consider a nonhormonal form of birth control) - affects warfarin (an anticoagulant) and certain drugs for HIV

III.

DRUGS

FOR

LEPROSY (HANSEN’S DISEASE)

- leprosy is a chronic infectious disease - if left untreated, can cause grotesque disfiguration - with the drugs available today, most patients can be cured - affects the skin, peripheral nerves, and mucous membranes of the upper respiratory tract - characteristic features are skin lesions with local loss of sensation, thickening of peripheral nerves, and acid-fast bacilli in smears from skin lesions - cornerstone of treatment is multi-drug therapy - most regimens include rifampin - can take these drugs for up to 12 months

1.

Pharmacology of Individual Antileprosy Drugs a. Rifampin – most effective agent for treating leprosy - most effective than any combination of other agents - monthly administration is just as effective as daily administration - less expressive - minimizes adverse effects, including hepatoxicity b.

Dapsone – absorbed rapidly and nearly completely from the GI

tract - widely distributed to tissues and body fluids - undergoes hepatic metabolism followed by excretion in the urine - generally well tolerated - most common adverse effects are GI disturbances, headache, rash, and a syndrome that resembles mononucleosis - hemolytic anemia occurs occasionally c.

Clofazimine – trade name Lamprene - administered orally and undergoes partial absorption - retained in fatty tissue and the skin - very safe and dangerous reactions are rare - GI symptoms (nausea, vomiting, cramping,

diarrhea) are common - imparts a harmless red color to feces, urine, sweat, tears, and saliva - deposition in the small intestine produces the most serious effects: intestinal obstruction, pain and bleeding - causes reversible reddish-black discoloration of the skin in most patients

Related Documents